Treatment of biofilm-associated infections is challenging, requiring the development of new therapeutic strategies. In this viewpoint, we discuss the use of nanoparticle-based systems as active therapeutic agents and as vehicles to transport drugs to the site of infection. These applications require understanding of the surface interactions of nanoparticles with bacteria/biofilms, an aspect that we likewise summarize.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: